The Latest Breaking News on Pharma

Given growing healthcare spending, supportive government policies, and technological innovation, the biotechnology industry is poised for solid long-term growth. Thus, investors could consider buying quality biotech stocks Harmony Biosciences (HRMY), Esperion Therapeutics (ESPR), and Entrada Therapeutics (TRDA), which are trading at a discount. Read on….

Social media and messaging apps such as Facebook, Instagram, Snapchat and Messenger are increasingly used to buy and sell drugs in many countries. New Zealand is no exception.

An NHS trust’s attempts to bring a crucial drug to market itself is hopeful news for patients, says Dr Catriona Crombie of the medical charity LifeArc

Amid surging medicine demand and ongoing drug shortages, the pharmaceutical industry thrives, driving improved patient outcomes and promising growth opportunities for investors. So, it could be wise to invest in quality pharma stocks ACADIA Pharmaceuticals (ACAD), Neurocrine Biosciences (NBIX), and Supernus Pharmaceuticals (SUPN), which can help you fetch potential financial…

The pharmaceutical industry is expanding owing to the rising incidence of chronic diseases, increasing investments in R&D, and the use of advanced technologies for drug development and manufacturing. Given this backdrop, investors could consider buying quality pharma stocks such as Elanco Animal Health (ELAN), Viatris (VTRS), and Astellas Pharma (ALPMY),…

Although dogged by controversy, the firm’s coronavirus jab saved the lives of millions and helped avert humanitarian crises in nations unable to access costly alternatives

Punjab Police busted an inter-state illegal pharmaceutical supply and manufacturing network operating from a pharma factory in Himachal Pradesh. Read further on Dynamite News:

With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be…

The drugmaker increased its market share of the diabetic treatment market by 1.8 percentage points and now has a 34-percent share of the market.